search
Back to results

The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers

Primary Purpose

Liver Cirrhosis

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Fibroscan
Sponsored by
University of Saskatchewan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Liver Cirrhosis

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

-Any outpatient undergoing routine pacemaker interrogation at pacemaker clinic

Exclusion Criteria:

  • Pregnancy
  • BMI>35
  • Person with active implantable medical devices other than cardiac pacemaker and/or ICD
  • Person who are unable to tolerate lying flat for the FibroScan examination.

Sites / Locations

  • Royal University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fibroscan

Arm Description

Fibroscan under simultaneous cardiac monitoring

Outcomes

Primary Outcome Measures

Rate of Pacemaker/ICD malfunction
Type of Pacemaker/ICD malfunction

Secondary Outcome Measures

Full Information

First Posted
April 8, 2015
Last Updated
May 13, 2016
Sponsor
University of Saskatchewan
search

1. Study Identification

Unique Protocol Identification Number
NCT02415348
Brief Title
The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers
Official Title
The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers and/or Implantable Cardioverter-Defibrillators
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Unknown status
Study Start Date
April 2015 (undefined)
Primary Completion Date
August 2016 (Anticipated)
Study Completion Date
August 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Saskatchewan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to determine if the Fibroscan (Echosens, Paris), a non-invasive, ultrasound-based device used to estimate fibrosis in patients with chronic liver disease, interferes with implanted cardiac pacemaker and/or implantable cardioverter-defibrillators. Recruitment consists of a total of 200 outpatients undergoing routine pacemaker interrogation at a teaching-hospital pacemaker clinic.
Detailed Description
Assessment of liver fibrosis in patients with chronic liver diseases provides staging and prognostic information critical in establishing treatment priorities. The gold standard evaluation of liver fibrosis is hampered by the invasive nature of liver biopsies. FibroScan is a non-invasive alternative that has been extensively validated in chronic hepatitis C, chronic hepatitis B, alcoholic liver disease, and non- alcoholic fatty liver disease patients. To avoid unknown risks of potential interaction, the manufacturer have advised against the use of the device in patients with active implantable medical device including cardiac pacemaker and/or implantable cardioverter-defibrillators(ICD). Review of the literature showed that these two population have been specifically excluded in all previously reported studies. At the time of writing, no specific reports have demonstrated either safety or potential harm of the FibroScan in patients with pacemaker/ICD. Given the proven benefit of the FibroScan in chronic liver disease and the current policy of excluding patients with pacemaker/ICD in clinical practice, this study aims to formally evaluate the safe use of the FibroScan in this population within the controlled environment of a pacemaker lab.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Cirrhosis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fibroscan
Arm Type
Experimental
Arm Description
Fibroscan under simultaneous cardiac monitoring
Intervention Type
Device
Intervention Name(s)
Fibroscan
Primary Outcome Measure Information:
Title
Rate of Pacemaker/ICD malfunction
Time Frame
30 min
Title
Type of Pacemaker/ICD malfunction
Time Frame
30 min

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: -Any outpatient undergoing routine pacemaker interrogation at pacemaker clinic Exclusion Criteria: Pregnancy BMI>35 Person with active implantable medical devices other than cardiac pacemaker and/or ICD Person who are unable to tolerate lying flat for the FibroScan examination.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lawrence Worobetz, MD
Organizational Affiliation
University of Saskatchewan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal University Hospital
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 0W8
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers

We'll reach out to this number within 24 hrs